Background: Multidrug resistance (MDR) is a major obstacle in breast cancer treatment. The predominant mechanism underlying MDR is an increase in the activity of adenosine triphosphate (ATP)-dependent drug efflux transporters. Sulbactam, a β-lactamase inhibitor, is generally combined with β-lactam antibiotics for treating bacterial infections. However, sulbactam alone can be used to treat Acinetobacter baumannii infections because it inhibits the expression of ATP-binding cassette (ABC) transporter proteins. This is the first study to report the effects of sulbactam on mammalian cells.
Background
Breast cancer, the most common cancer in women, annually affects 1.8 million women worldwide [1] . Approximately 12% of women in the United States are estimated to receive diagnoses of breast cancer in their lifetime [2] . Breast cancer is classified into three subtypes according to the expression of receptors: hormone (estrogen and progesterone)-receptor-positive breast cancer, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and triple-negative breast cancer (TNBC; lacking hormone receptors as well as HER2) [3] . Patients with TNBC exhibit a high risk of early tumor recurrence and poor prognosis [4] . Chemotherapy is a principal treatment for breast cancer, but resistance to chemotherapy-occurring in at least a quarter of all cases-is a major problem in breast cancer management, causing treatment failure in more than 90% of patients with metastatic cancers [5] [6] [7] [8] . The mechanisms underlying resistance in different breast cancer subtypes are diverse, complex, and unclear. Cancer cells may develop resistance to a specific class of cytotoxic drugs owing to changes in target proteins and in cellular biological activities affecting the efficacy of the drugs. The changes include increased repair of DNA damage and decreased apoptosis, membrane permeability, and drug metabolism. Furthermore, the uptake of water-soluble drugs decreases due to a decrease in the expression of transporter proteins responsible for drugs to enter the cells and the energy-dependent efflux of hydrophobic drugs increases, for instance, through increased expression of adenosine triphosphate (ATP)-binding cassette (ABC) transporter proteins [9] [10] [11] [12] [13] [14] [15] .
Doxorubicin, an anthracycline antibiotic, has been considered one of the most effective agents in breast cancer treatment since the 1970s [16] . Doxorubicin mainly intercalates between DNA bases and subsequently inhibits topoisomerase II activity, thus impairing DNA synthesis [17] . Doxorubicin also generates free radicals, which damage DNA and cell membranes [18] . Doxorubicin enters the cells through passive diffusion and accumulates intracellularly, particularly in the nuclear compartments [19] . However, doxorubicin is nonselective toward cancer cells; thus, it causes toxicity in the heart, brain, liver, and kidneys [19, 20] . The most prominent adverse event is life-threatening cardiotoxicity, which limits the prescribed dose of doxorubicin [20] . Doxorubicin resistance is another crucial cause of treatment failure [3] . The reported response rates to doxorubicin as a single agent for breast cancer treatment were 43% and 28% in patients who were exposed to doxorubicin for the first time and those who had been exposed to the drug for more than once, respectively. Thus, nearly 50% of the treated patients developed resistance to doxorubicin, making resistance the major cause of treatment failure [21] . The predominant mechanism underlying resistance to doxorubicin in breast cancer cells is the overexpression of a few ABC transporter proteins that increase doxorubicin efflux, thus decreasing intracellular drug concentrations [3, 9, 22] . Other mechanisms underlying doxorubicin resistance include alterations in cellular signaling pathways, leading to failure of apoptosis, and changes in gene expression, resulting in a chemoresistant phenotype [3, 19] .
Increased expression of ABC transporter proteins has been correlated with poor clinical prognosis in patients with breast cancer of any subtype [23, 24] . The human genome has 49 members of the ABC transporter family, divided into seven subfamilies (ABCA-ABCG) based on their sequence similarities [25] . These membrane proteins actively pump various structurally and functionally diverse amphipathic anticancer drugs from inside the tumor cells to the outside, thereby decreasing intracellular drug concentrations and causing chemotherapeutic drug resistance [9, 10] . The primary members of the ABC transporter family leading to doxorubicin resistance in cancer cells are the ABCBs, the ABCCs [also known as multidrug resistance (MDR)-associated proteins], and ABCG2 (also known as breast cancer resistance protein, mitoxantrone resistance protein, or placenta-specific ABC transporter) [9, 26, 27] . Among the aforementioned ABC transporter proteins, ABCB1 [a P-glycoprotein, (p-gp)], ABCC1, and ABCG2 have been extensively characterized in breast cancers [23, 24, 28, 29] . Inhibitors of the ABC transporter proteins activity were used to overcome ABC transporter-mediated MDR for obstructing the expression of the transporter proteins or inhibiting their function. For example, a combination of doxorubicin and verapamil, a P-gp inhibitor, can reverse the resistance of breast cancer cells to doxorubicin [30] . However, verapamil can potentiate the cardiotoxicity of doxorubicin [31] . Over the past decades, numerous inhibitors of MDR-related ABC transporter proteins have been developed and identified. However, the development of most inhibitors has been discontinued because of their low binding affinity, toxicity, detrimental pharmacokinetic interactions, and low patient survival advantages [9, 32] . Furthermore, the expression patterns of ABC transporter proteins in breast cancer cells are heterogeneous; thus, the efficacy of inhibitors specific to some ABC transporter proteins is low [33] .
Sulbactam, a β-lactamase inhibitor belonging to Ambler class A, is administered along with β-lactam antibiotics (e.g., ampicillin and penicillin) to prevent the hydrolysis of the antibiotics by bacterial β-lactamases. Sulbactam inhibits the activity of β-lactamases by irreversibly binding to their active sites. The β-lactam/β-lactamase inhibitor combination has been approved by the US Food and Drug Administration for treating dermatological, gynecological, and intraabdominal infections [34] . Although sulbactam has relatively low intrinsic biological activity, it has inherent activity against some bacterial species, including Neisseria gonorrhoeae, Bacteroides fragilis, and Acinetobacter spp. [35, 36] . Preliminary in vitro experiments have demonstrated that sulbactam kills bacteria by binding to the penicillin-binding proteins (PBPs) of Acinetobacter spp. and downregulating the expression of PBP1 and PBP3 [35, 37] . Furthermore, sulbactam reduces the expression of the ABC transporter proteins in Acinetobacter baumannii [38] . The ABC transporter superfamilies are highly conserved protein families, and their structural features and mechanisms of action have been conserved from prokaryotes to humans [39, 40] . Thus, we hypothesized that if sulbactam can reduce the expression of ABC transporter proteins in breast cancer cells, then it can reduce the efflux of doxorubicin from breast cancer cells and enhance its efficacy.
Materials and methods

Reagents
Doxorubicin hydrochloride was purchased from SigmaAldrich (St. Louis, MO, USA). Sulbactum sodium was obtained from TTY Biopharm (Taiwan). Verapamil was obtained from Orion Pharma (Espoo, Finland).
Cell lines and cell culture
The breast carcinoma cell lines MDA-MB-231, MDA-MB-435, MDA-MB-453, and MDA-MB-468 were maintained in Dulbecco's modified Eagle's medium (DMEM) (Hyclone, Thermo Fisher Scientific Inc. Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Gibco-BRL, Rockville, MD, USA) and 100 units/mL penicillin-streptomycin (Gibco-BRL). The breast carcinoma cell lines MCF-7, BT474, and T-47D were maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (Hyclone) containing 10% FBS and 100 units/mL penicillin-streptomycin. The human breast epithelial cell line MCF-10A was maintained in DMEM/F12 medium containing 5% horse serum (Invitrogen, Carlsbad, CA, USA), 20 ng/mL epithelial growth factor (Peprotech, Rocky Hill, NJ, USA), 0.5 μg/mL hydrocortisone (Sigma-Aldrich), 10 μg/mL insulin (Sigma-Aldrich), and 100 units/mL penicillin-streptomycin. All cell lines were incubated at 37 °C and 5% CO 2 .
MTT assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to access cytotoxicity. The cells were grown in 96-well plates at a density of 1. 
Efflux assay of doxorubicin
The MDA-MB-453 and MDA-MB-468 cells were seeded on coverslips in 12-well plates at a concentration of 1 × 10 5 cells/well and grown for 16 h. On the following day, the cells were washed with phosphate buffered saline (PBS) and incubated with 2 mM sulbactam or 5 µM verapamil for 30 min before treating them with 2 µM doxorubicin for 2 h. The cells were subsequently incubated in a doxorubicin-free medium for 0, 8, 12 , and 16 h. Images were obtained using a LSM 780 confocal microscope (Zeiss) and analyzed using ZEN 2012.
Gel electrophoresis
The equivalence of the human cell lines was analyzed through 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The gels were then stained using the VisPRO protein stain kit (Visual Protein Biotech, Taiwan) for 5 min. After staining, the gels were washed with Milli-Q water and stored at 4 °C until in-gel digestion.
In-gel digestion
The gel lanes corresponding to the samples were cut into five slices, and each slice was subjected to in-gel digestion according to the method of Shevchenko [41] . Briefly, the slices were washed thrice with 50 mM ammonium bicarbonate (pH 7.9) and dehydrated using 50 mM AMBC + 50% acetonitrile (ACN). Subsequently, the cysteine bonds were reduced after treatment with 10 mM dithiothreitol for 1 h at 56 °C and alkylated using 50 mM 4-vinylpyridine for 45 min at room temperature in the dark. After two subsequent wash-dehydration cycles, the slices were dried for 10 min in a vacuum centrifuge (ThermoFisher, Breda, Netherlands) and incubated overnight with 6.25 ng/μL trypsin in 50 mM AMBC at 25 °C. The resulting peptides were extracted once in 100 μL of 1% formic acid and then two times in 100 μL of 50% ACN in 5% formic acid. The volume was reduced to 50 μL in a vacuum centrifuge before liquid chromatography (LC)-tandem mass spectrometry (MS/MS) analysis.
LC-MS/MS
The peptides were separated using an Ultimate 3000 nano LC system (Dionex LC-Packings, Amsterdam, Netherlands) equipped with a 20 cm × 75 μm internal diameter (i.d.) fused-silica column custom packed with 3-μm 120-Å ReproSil Pur C18 aqua (Dr. Maisch, GMBH, Ammerbuch-Entringen, Germany). After injection, the peptides were delivered into the column at a flowrate of 30 μL/min and trapped on a 5 mm × 300 μm i.d. Pepmap C18 cartridge (Dionex LC-Packings), which were then eluted by 2% buffer B (80% ACN and 0.05% formic acid in Milli-Q water) and separated at 300 nL/min in a 10%-40% buffer B gradient within 60 min. The eluting peptides were ionized at 1.7 kV in a Nanomate Triversa Chip-based nanospray source by using a Triversa LC coupler (Advion, Ithaca, NJ, USA). Intact peptide mass spectra and fragmentation spectra were acquired on a LT QFT hybrid mass spectrometer (Thermo Fisher, Bremen, Germany). The intact masses were measured at a resolution of 50,000 in the ion cyclotron resonance (ICR) cell by using a target value of 1 × 10 6 charges. Simultaneously, following an FT prescan, the five highest peptide signals (charge states 2+ and higher) were submitted for MS/MS in the linear ion trap (3-AMU isolation width, 30 ms activation, 35% normalized activation energy, 0.25 Q-value, and 5000-count threshold. Dynamic exclusion was applied with a repeat count of 1 and an exclusion time of 30 s.
Results
Sulbactam potentiates doxorubicin sensitivity in breast cancer cells
To determine whether sulbactam enhances the cytotoxicity of doxorubicin, MCF-10A (normal), BT474 (ER/PR+, Her2+), MCF-7 (ER/PR+, Her2−), MDA-MB-231 (triple negative), MDA-MB-361 (ER/PR+, Her2+), MDA-MB-435 (ER/PR−, Her2+), MDA-MB-453 (triple negative), MDA-MB-468 (triple Table 1 Fig. 1) . When the cells were treated with doxorubicin alone, the viability of the MDA-MB-468 cells was < 50% at 0.5 µM doxorubicin, the viabilities of the MCF-7, MDA-MB-361, and MDA-MB-453 cells were < 50% at 1 μM doxorubicin, the viabilities of the BT474, MDA-MB-231, and MDA-MB-435 cells were < 50% at 5 μM doxorubicin, and the viability of T47D cells was < 50% until the concentration of doxorubicin reached 10 μM. Among these breast cancer cell lines, the T47D cell line exhibited low sensitivity to doxorubicin, with a IC50 value of 8.53 µM (Fig. 1i) . By contrast, the MDA-MB-453 and MDA-MB-468 cells were more sensitive to doxorubicin than the T47D cells; they had lower IC 50 values (0.69 and 0.27 μM, respectively) than the T47D cells and had the lowest viabilities at 5 and 10 μM doxorubicin (Fig. 1g, h ). Next, we analyzed whether sulbactam enhanced the cytotoxicity of doxorubicin in the breast cancer cells. When the cells were treated with a combination of sulbactam and doxorubicin, the viabilities of the eight breast cancer cell lines significantly decreased (Fig. 1b-i (Fig. 2) . However, when combined with 0.5 μM doxorubicin, sulbactam potentiated the cytotoxicity of doxorubicin without evident dose dependence in the MDA-MB-453 and MDA-MB-468 cells. Thus, sulbactam has low cytotoxicity and can enhance the sensitivity of breast cancer cells toward doxorubicin.
Proteomic profiling of total proteins from MDA-MB-468 cells treated with and without sulbactam in presence of doxorubicin
The MDA-MB-468 cells were treated with or without 2 mM sulbactam in the presence of 0.1 μM doxorubicin for 24 h. The total cell lysates were harvested for LC-MS/ MS analysis. In total, 2937 proteins were identified using Sequest, which were validated using Scaffold. The expression of 66 and 70 proteins were significantly upregulated and downregulated, respectively, in the MDA-MB-468 cells treated with a combination of sulbactam and doxorubicin (based on p value < 0.05 and fold change > 2; Tables 3 and 4 ). The UniProt database was used to classify the identified proteins according to their biological processes. The upregulated proteins were classified as RNA processing, response to DNA damage, response to stress, cytoskeleton organization, protein folding, ubiquitin-dependent protein catabolic process, vesicle-mediated transport, carbohydrate metabolism, amino acid metabolism, and positive regulation of apoptosis proteins ( Table 3 ). The downregulated proteins were classified as translation, regulation of transcription, RNA processing, ABC transporter, cytoskeleton organization, protein folding, protein catabolic process, carbohydrate metabolism, mitochondrial metabolic process, negative regulation of apoptosis, and signal transduction proteins ( Table 4) . The connections among the proteins and GO biological processes of the proteins were tested through STRING network analysis. The proteins are represented as nodes. The thickness of the edges indicates the strength of correlations between the proteins according to neighborhood, gene fusion, co-occurrence, co-expression, previous experiments, databases, and text-mining information at confidence scores higher than 0.5. As shown in Fig. 3a, 38 of the 60 proteins which were upregulated in the MDA-MB-468 cells treated with a combination of sulbactam and doxorubicin were associated with response to stimuli. Functional clusters included proteins involved in carbohydrate metabolism, tubulin-associated cytoskeleton organization, and ubiquitin-dependent protein catabolic process. As shown in Fig. 3b, 31 of 68 proteins which were downregulated in the MDA-MB-468 cells treated with a combination of sulbactam and doxorubicin were associated with gene expression. The functional clusters of these downregulated proteins were associated with actin remodeling, mitochondrial metabolic process, protein catabolic process, transcription and RNA process, and translation. (Fig. 4) . Sulbactam also moderately reduced the mRNA expression of 
Sulbactam downregulates mRNA levels of ABC transporters in breast cancer cell lines
Sulbactam prolongs doxorubicin retention in breast cancer cells
To investigate whether the sulbactam-induced reduction in the expression of ABC transporters inhibits the efflux of doxorubicin, the distribution of doxorubicin in breast cancer cells was observed using a confocal microscope. A time-course study was performed in the presence and absence of sulbactam. For comparison, the cells were also pretreated with verapamil, a wellknown inhibitor of ABCB1 and ABCG2. The fluorescent signal corresponding to doxorubicin was primarily observed in nuclei of the cells, and the concentration of doxorubicin decreased time-dependently (Fig. 5) 
Discussion
The coadministration of sulbactam and a β-lactam antibiotic, such as ampicillin, is an effective therapy against bacteria, such as A. baumannii [42] . Sulbactam alone has intrinsic bactericidal effects against multidrug-resistant A. baumannii because it inhibits the expression of the ABC transporters as well as that of 30S and 50S ribosomal subunit proteins [38] . The results of LC-MS/MS indicated that most of the upregulated proteins (21/66) associated with stress and DNA damage response, such as heat shock-related 70-kDa protein 2 and adenomatous polyposis coli protein, may respond to the stress caused by sulbactam. When used as a drug, sulbactam also stimulates some metabolic pathways and cytoskeleton organizations, such as carbohydrate metabolism and tubulin-associated cytoskeleton organization. In the presence of doxorubicin and sulbactam evidently inhibited the initiation of RNA processing, transcription, and translation (Fig. 6 ). Doxorubicin interacts with DNA through intercalation between bases and macromolecular biosynthesis inhibition [19] . This inhibits the progression of topoisomerase II, which relaxes supercoils in DNA during transcription. Through intercalation, doxorubicin can also induce histone eviction from transcriptionally active chromatin [43] . Consequently, here, RNA processing and translation were downregulated in the doxorubicin-exposed cells. Sulbactam increased the doxorubicin retention time in the breast cancer cells. Therefore, in the presence of sulbactam, the effects of doxorubicin on transcription and translation were enhanced, and the 60S ribosomal proteins, namely L4, L17, L24, L37a, and 40S ribosomal protein 3A, and translation initiation-associated proteins, namely eIF1A, eIF3, eIF4G1, eIF6, and eEF1B, were downregulated. Hence, the initiation of the translation pathway was inhibited (Fig. 6) . The results of LC-MS/MS also indicated that the expression of ABC transporter proteins ABCA8, ABCB1, and ABCG2 were downregulated, corresponding to our previous finding that sulbactam inhibits ABC transporters of A. baumannii and thus kills the bacterium [38] . Most ABC transporter families are transmembrane proteins, which are difficult to isolate and identify through total protein LC-MS/MS; hence, we used real-time RT-PCR to determine the effects of sulbactam on the mRNA expression of the ABC transporter proteins. The expression of ABC transporter proteins in breast cancer cells is highly heterogeneous [33, 44] ; thus, we selected the ABCB superfamily, the ABCC superfamily, and ABCG2, which are strongly associated with drug resistance in breast cancer cells [23, 26, 32] . Based on the results of other studies and our PCR analysis, we selected ABCB1, ABCB2, ABCB8, ABCB10, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC10, and ABCG2, which exhibit high mRNA expression levels for precise real-time RT-PCR analysis.
Although the effects of sulbactam on these ABC transporters were different in MDA-MB-453 and MDA-MB-468 cells, we conclude that in the presence of sulbactam and doxorubicin, the mRNAs levels of the indicated ABC transporter proteins were evidently downregulated. ABCB1, ABCB5, ABCB8, ABCC1, ABCC2, ABCC3, and ABCG2 [22, [45] [46] [47] [48] were considered to confer resistance to doxorubicin on the breast cancer cells. We further found that ABCB10, ABCC4, and ABCC5 in the MDA-MB-453 cells and ABCB10, ABCC5, and ABCC10 in the MDA-MB-468 cells also responded to sulbactam treatment. Studies have reported that ABCB5, ABCB8, ABCB10, ABCC2-5, and ABCC10 are overexpressed in breast cancer cells or are associated with breast cancer progression [44, [49] [50] [51] [52] [53] . Our doxorubicin efflux assay also indicated that in the presence of sulbactam, the retention time of doxorubicin in MDA-MB-453 and MDA-MB-468 cells was prolonged significantly. We used the computer simulation and found that sulbactam may compete with ATP for the ATPdocking sites of ABCB1, ABCB10, ABCC1, and MsbA, which exhibit structures similar to the ABCG2 (data not shown). This result provides a possibility how sulbactam 
Conclusion
In conclusion, this is the first study that using sulbactam in the mammalian cell. The combination of sulbactam and doxorubicin can enhance the cytotoxicity of doxorubicin in the breast cancer cells by inhibiting the transcription and initiation of translation associated proteins and ABC transporters, reducing their expression, and blocking the efflux of doxorubicin, thus triggering apoptosis in the breast cancer cells. From these results, sulbactam can be used in breast cancer treatment which can decrease the prescribed dose of doxorubicin to avoid the adverse effects.
